Share on Pinterest A new trial finds that GLP-1 agonists may help reduce knee osteoarthritis-related pain. Westend61/Getty ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...

The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found.People who r ...

Osteoarthritis, the most common form of arthritis, is primarily caused by wear and tear on the protective layer of cartilage ...

The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in obesity and knee osteoarthritis.

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.

Recent research has found that semaglutide injections, which also include controversial weight loss drug Ozempic, can reduce ...

FRIDAY, Nov. 1, 2024 (HealthDay News) -- The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found. People who received weekly injections of ...

HealthDay News — For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and pain related to knee osteoarthritis than placebo, according ...